Murate T - Search Results

1

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.

Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y, Morishima Y, Murate T, Kasai M, Uike N, Taniwaki M, Kano Y, Ohnishi K, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Tobinai K; IDEC-C2B8 Study Group in Japan. Igarashi T, et al. Among authors: murate t. Ann Oncol. 2002 Jun;13(6):928-43. doi: 10.1093/annonc/mdf155. Ann Oncol. 2002. PMID: 12123339 Free article. Clinical Trial.

2

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.

Tobinai K, Kobayashi Y, Narabayashi M, Ogura M, Kagami Y, Morishima Y, Ohtsu T, Igarashi T, Sasaki Y, Kinoshita T, Murate T. Tobinai K, et al. Among authors: murate t. Ann Oncol. 1998 May;9(5):527-34. doi: 10.1023/a:1008265313133. Ann Oncol. 1998. PMID: 9653494 Free article. Clinical Trial.

3

A high dose chemoradiotherapy and peripheral blood stem cell support combined with the CD34(+)-selection method in cyclin D1(+)-mantle cell lymphoma.

Uehira K, Kagami Y, Ogura M, Suzuki R, Miura K, Tachi H, Kurokawa T, Kinoshita T, Murate T, Nakamura S, Morishima Y. Uehira K, et al. Among authors: murate t. Int J Hematol. 1998 Feb;67(2):187-90. doi: 10.1016/s0925-5710(97)00097-2. Int J Hematol. 1998. PMID: 9631586

4

CD20-negative relapse in B-cell lymphoma after treatment with Rituximab.

Kinoshita T, Nagai H, Murate T, Saito H. Kinoshita T, et al. Among authors: murate t. J Clin Oncol. 1998 Dec;16(12):3916. J Clin Oncol. 1998. PMID: 9850038 No abstract available.

5

Complementarity determining region-III is a useful molecular marker for the evaluation of minimal residual disease in mantle cell lymphoma.

Kurokawa T, Kinoshita T, Murate T, Nagasaka T, Kagami Y, Ogura M, Nakamura S, Seto M, Hotta T, Saito H. Kurokawa T, et al. Among authors: murate t. Br J Haematol. 1997 Aug;98(2):408-12. doi: 10.1046/j.1365-2141.1997.2133030.x. Br J Haematol. 1997. PMID: 9266940 Free article.

6

CDKN2 (MTS1/p16INK4A) gene alterations in adult T-cell leukemia/lymphoma.

Uchida T, Kinoshita T, Murate T, Saito H, Hotta T. Uchida T, et al. Among authors: murate t. Leuk Lymphoma. 1998 Mar;29(1-2):27-35. doi: 10.3109/10428199809058379. Leuk Lymphoma. 1998. PMID: 9638973 Review.

7

High-risk myelodysplastic syndromes and hypermethylation of the p15Ink4B gene.

Uchida T, Kinoshita T, Hotta T, Murate T. Uchida T, et al. Among authors: murate t. Leuk Lymphoma. 1998 Dec;32(1-2):9-18. doi: 10.3109/10428199809059242. Leuk Lymphoma. 1998. PMID: 10036997 Review.

8

Molecular evaluation of bone marrow involvement in peripheral T-cell lymphoma with a PCR-mediated RNase protection assay.

Hanamura A, Kinoshita T, Kurokawa T, Nagai H, Murate T, Nagasaka T, Mori H, Saito H. Hanamura A, et al. Among authors: murate t. Int J Hematol. 1999 Dec;70(4):283-9. Int J Hematol. 1999. PMID: 10643155

9

The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin.

Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, Murate T, Saito H. Watanabe T, et al. Among authors: murate t. Blood. 1994 Nov 1;84(9):3158-65. Blood. 1994. PMID: 7949188 Free article.

10

Identification and mapping of novel tumor suppressor loci on 6p in diffuse large B-cell non-Hodgkin's lymphoma.

Nagai H, Kinoshita T, Suzuki H, Hatano S, Murate T, Saito H. Nagai H, et al. Among authors: murate t. Genes Chromosomes Cancer. 1999 Jul;25(3):277-83. Genes Chromosomes Cancer. 1999. PMID: 10379874

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

204 results

Search Page